Veracyte (NASDAQ: VCYT) insider transactions

In the twelve months to 10 November 2026, executives and directors of Veracyte reported 50 open-market sales of 426,811 shares ($19.2m) and 0 open-market purchases, by 11 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Veracyte shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
28 October 2026	Wygant Jonathan	VP, Chief Accounting Officer	Shares withheld for tax	−1,306	$50.31	41,920	Form 4
27 October 2026	Eastham Karin	Director	Option exercise, 10b5-1 plan	+10,000	$27.01	25,097	Form 4
27 October 2026	Eastham Karin	Director	Open-market sale, 10b5-1 plan	−14,850	$50.00	10,247	Form 4
27 October 2026	Holstein Jens	Director	Option exercise, 10b5-1 plan	+7,500	$35.30	34,971	Form 4
27 October 2026	Holstein Jens	Director	Open-market sale, 10b5-1 plan	−7,500	$50.00	27,471	Form 4
19 October 2026	Bhanji Muna	Director	Open-market sale, 10b5-1 plan	−1,864	$43.70	40,854	Form 4
24 September 2026	Holstein Jens	Director	Option exercise, 10b5-1 plan	+7,500	$35.30	34,971	Form 4
24 September 2026	Holstein Jens	Director	Open-market sale, 10b5-1 plan	−7,500	$47.00	27,471	Form 4
21 September 2026	Leite John	Global Chief Commercial Off	Open-market sale, 10b5-1 plan	−4,015	$40.00	124,329	Form 4
14 September 2026	Holstein Jens	Director	Open-market sale, 10b5-1 plan	−5,000	$40.95	27,471	Form 4
4 September 2026	Febbo Phillip G.	Chief Scientific & Med Officer	Open-market sale, 10b5-1 plan	−10,405	$42.89	135,753	Form 4
4 September 2026	Febbo Phillip G.	Chief Scientific & Med Officer	Open-market sale, 10b5-1 plan	−2,705	$43.66	133,048	Form 4
4 September 2026	Chambers Rebecca	Chief Financial Officer	Open-market sale, 10b5-1 plan	−2,477	$42.81	167,200	Form 4
4 September 2026	Chambers Rebecca	Chief Financial Officer	Open-market sale, 10b5-1 plan	−1,175	$43.71	166,025	Form 4
4 September 2026	McGuire Annie	EVP, General Counsel	Open-market sale, 10b5-1 plan	−2,154	$42.79	132,260	Form 4
4 September 2026	McGuire Annie	EVP, General Counsel	Open-market sale, 10b5-1 plan	−1,100	$43.67	131,160	Form 4
2 September 2026	Stapley Marc	Chief Executive Officer	Shares withheld for tax	−8,782	$44.88	432,073	Form 4
2 September 2026	Wygant Jonathan	VP, Chief Accounting Officer	Shares withheld for tax	−1,361	$44.88	43,226	Form 4
2 September 2026	Febbo Phillip G.	Chief Scientific & Med Officer	Shares withheld for tax, 10b5-1 plan	−3,639	$44.88	146,158	Form 4
2 September 2026	Chambers Rebecca	Chief Financial Officer	Shares withheld for tax, 10b5-1 plan	−3,603	$44.88	169,677	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Veracyte page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.